Track Cyclacel Pharmaceuticals, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Cyclacel Pharmaceuticals, Inc. CYCCP · Stock Open Cyclacel Pharmaceuticals, Inc. in new tab

5.05 USD
Yield
11.88%
Safety Score
17
Loading chart...
Dividend
Dividend Yield11.88%
Annual dividends0.60 USD
Ex-Div. DateOct. 26, 2026
Payout-7.26%

DCF valuation

Model fair value for Cyclacel Pharmaceuticals, Inc. (CYCCP)
Result
Sign in to run the valuation for CYCCP.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–

Cyclacel Pharmaceuticals, Inc. Logo Cyclacel Pharmaceuticals, Inc. Analysis (CYCCP)

United States Health Care Official Website Stock

Is Cyclacel Pharmaceuticals, Inc. a good investment? Cyclacel Pharmaceuticals, Inc. (CYCCP) is currently trading at 5.05 USD.

For income investors, Cyclacel Pharmaceuticals, Inc. pays a dividend yield of 11.88%. With a payout ratio of -7%, the dividend appears sustainable.

Investor FAQ

Does Cyclacel Pharmaceuticals, Inc. pay a dividend?

Yes, it pays an annual dividend of 0.60 USD (11.88% yield).

What asset class is Cyclacel Pharmaceuticals, Inc.?

Cyclacel Pharmaceuticals, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

Company Profile

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.

Exchange Ticker
NCM (Australia) CYCCP
Trades
Dividend Yield
11.88%
Annual Dividends
0.60USD
Next Ex. Div Date
Oct. 26, 2026
Payout Ratio
-7.26%
Dividend History paid per year (USD)
Historical Dividends
Year Total Dividends
▸2027
0.45 USD
Aug. 2, 2027 (estimated) 0.1500
May 3, 2027 (estimated) 0.1500
Feb. 1, 2027 (estimated) 0.1500
▸2026
0.60 USD
Nov. 1, 2026 0.1500
Aug. 1, 2026 0.1500
May 1, 2026 0.1500
Feb. 1, 2026 0.1500
▸2025
0.45 USD
Nov. 1, 2025 0.1500
Aug. 1, 2025 0.1500
May 1, 2025 0.1500
▸2024
0.15 USD
Feb. 1, 2024 0.1500
▸2023
0.60 USD
Nov. 1, 2023 0.1500
Aug. 1, 2023 0.1500
May 1, 2023 0.1500
Feb. 1, 2023 0.1500
▸2022
0.60 USD
Nov. 1, 2022 0.1500
Aug. 1, 2022 0.1500
May 1, 2022 0.1500
Feb. 1, 2022 0.1500
▸2021
0.60 USD
Nov. 1, 2021 0.1500
Aug. 1, 2021 0.1500
May 1, 2021 0.1500
Feb. 1, 2021 0.1500
▸2020
0.46 USD
Nov. 1, 2020 0.1500
Aug. 1, 2020 0.1500
May 1, 2020 0.0100
Feb. 1, 2020 0.1500
▸2019
0.60 USD
Nov. 1, 2019 0.1500
Aug. 1, 2019 0.1500
May 1, 2019 0.1500
Feb. 1, 2019 0.1500
▸2018
0.60 USD
Nov. 1, 2018 0.1500
Aug. 1, 2018 0.1500
May 1, 2018 0.1500
Feb. 1, 2018 0.1500
▸2017
0.60 USD
Nov. 1, 2017 0.1500
Aug. 1, 2017 0.1500
May 1, 2017 0.1500
Feb. 1, 2017 0.1500
▸2016
0.60 USD
Nov. 1, 2016 0.1500
Aug. 1, 2016 0.1500
May 1, 2016 0.1500
Feb. 1, 2016 0.1500
▸2015
0.60 USD
Nov. 2, 2015 0.1500
Aug. 3, 2015 0.1500
May 1, 2015 0.1500
Feb. 2, 2015 0.1500
▸2014
0.60 USD
Nov. 1, 2014 0.1500
Aug. 1, 2014 0.1500
May 1, 2014 0.1500
Feb. 3, 2014 0.1500
▸2013
0.60 USD
Nov. 1, 2013 0.1500
Aug. 1, 2013 0.1500
May 1, 2013 0.1500
Feb. 1, 2013 0.1500
▸2011
0.30 USD
May 2, 2011 0.1500
Feb. 1, 2011 0.1500
▸2009
0.15 USD
Jan. 30, 2009 0.1500
▸2008
0.60 USD
Nov. 1, 2008 0.1500
Aug. 1, 2008 0.1500
May 1, 2008 0.1500
Feb. 1, 2008 0.1500
▸2007
0.60 USD
Nov. 1, 2007 0.1500
Aug. 1, 2007 0.1500
May 1, 2007 0.1500
Feb. 1, 2007 0.1500
▸2006
0.60 USD
Nov. 1, 2006 0.1500
Aug. 1, 2006 0.1500
May 1, 2006 0.1500
Feb. 1, 2006 0.1500
▸2005
0.60 USD
Nov. 1, 2005 0.1500
Aug. 1, 2005 0.1500
May 2, 2005 0.1500
Feb. 1, 2005 0.1467
Upcoming Dividends
Name Payment Date Status Amount
Cyclacel Pharmaceuticals, Inc. Nov 01, 2026 0.15 USD
Cyclacel Pharmaceuticals, Inc. Aug 01, 2026 0.15 USD
Cyclacel Pharmaceuticals, Inc. May 01, 2026 0.15 USD
Cyclacel Pharmaceuticals, Inc. Feb 01, 2026 0.15 USD
Stock Splits
Split Date Split Ratio to 1
May 31, 2016 1:12
July 7, 2025 1:15
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion